Trust but Verify: Lessons Learned for the Application of AI to Case-Based Clinical Decision-Making From Postmarketing Drug Safety Assessment at the US Food and Drug Administration

被引:0
|
作者
Ball, Robert [1 ]
Talal, Andrew H. [2 ]
Dang, Oanh [1 ]
Munoz, Monica [1 ]
Markatou, Marianthi [3 ]
机构
[1] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
[2] Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[3] Univ Buffalo, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA
关键词
drug safety; artificial intelligence; machine learning; natural language processing; causal inference; case-based reasoning; clinical decision support; TEXT MINING SYSTEM; CAUSALITY ASSESSMENT; ADVERSE; CLASSIFICATION;
D O I
10.2196/50274
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Adverse drug reactions are a common cause of morbidity in health care. The US Food and Drug Administration (FDA) evaluates individual case safety reports of adverse events (AEs) after submission to the FDA Adverse Event Reporting System as part of its surveillance activities. Over the past decade, the FDA has explored the application of artificial intelligence (AI) to evaluate these reports to improve the efficiency and scientific rigor of the process. However, a gap remains between AI algorithm development and deployment. This viewpoint aims to describe the lessons learned from our experience and research needed to address both general issues in case-based reasoning using AI and specific needs for individual case safety report assessment. Beginning with the recognition that the trustworthiness of the AI algorithm is the main determinant of its acceptance by human experts, we apply the Diffusion of Innovations theory to help explain why certain algorithms for evaluating AEs at the FDA were accepted by safety reviewers and others were not. This analysis reveals that the process by which clinicians decide from case reports whether a drug is likely to cause an AE is not well defined beyond general principles. This makes the development of high performing, transparent, and explainable AI algorithms challenging, leading to a lack of trust by the safety reviewers. Even accounting for the introduction of large language models, the pharmacovigilance community needs an improved understanding of causal inference and of the cognitive framework for determining the causal relationship between a drug and an AE. We describe specific future research directions that underpin facilitating implementation and trust in AI for drug safety applications, including improved methods for measuring and controlling of algorithmic uncertainty, computational reproducibility, and clear articulation of a cognitive framework for causal inference in case-based reasoning.
引用
收藏
页数:14
相关论文
共 16 条
  • [1] Challenges to Making the Decision to Stop Mass Drug Administration for Onchocerciasis: Lessons Learned from Nigeria
    Evans, Darin S.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2020, 102 (03): : 485 - 486
  • [2] Ethical Decision-Making in Healthcare: An Interprofessional Approach - Eight Years of Lessons Learned in Case-Based Interprofessional Education
    Akerson, Emily
    Bryson, B. J.
    Gloeckner, Janet
    Stewart, Anne
    JOURNAL OF INTERPROFESSIONAL CARE, 2013, 27 : 6 - 6
  • [3] The decision-making process of US Food and Drug Administration Advisory Committees on switches from prescription to over-the-counter status: A comparative case study
    Nguyen, Nancy Thai
    Cook, Daniel M.
    Bero, Lisa A.
    CLINICAL THERAPEUTICS, 2006, 28 (08) : 1231 - 1243
  • [4] Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021
    Daval, C. Joseph Ross
    Teng, Theodore W.
    Russo, Massimiliano
    Kesselheim, Aaron S.
    JAMA HEALTH FORUM, 2023, 4 (07): : E231718
  • [5] Minor differences, major consequences? Lessons learned from replication of a claims-based drug safety assessment
    Huang, Ting-Ying
    Hou, Laura
    Shockro, Laura
    Pestine, Ella
    Nguyen, Michael
    Maro, Judith C.
    Izem, Rima
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 168 - 168
  • [6] DOSE-DEPENDENT FOOD EFFECT: LESSONS LEARNED FROM A SURVEY OF DRUGS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION BETWEEN 2003 AND 2019.
    Zou, P.
    Liu, J.
    Lu, Y.
    Seo, S.
    Tran, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S65 - S65
  • [7] OSTEOARTHRITIS CLINICAL TRIAL DESIGN AND FOOD AND DRUG ADMINISTRATION ACCELERATED APPROVAL: LESSONS LEARNED FROM THE OSTEOPOROSIS AND LIVER FIBROSIS FIELDS
    Karsdal, M. A.
    Bay-Jensen, A-C.
    Bihlet, A. R.
    Kraus, V. B.
    Byrjalsen, I.
    Andersen, J. R.
    OSTEOARTHRITIS AND CARTILAGE, 2018, 26 : S271 - S271
  • [8] OSTEOARTHRITIS CLINICAL TRIAL DESIGN AND FOOD AND DRUG ADMINISTRATION ACCELERATED APPROVAL: LESSONS LEARNED FROM THE OSTEOPOROSIS AND LIVER FIBROSIS FIELDS
    Karsdal, M. A.
    OSTEOARTHRITIS AND CARTILAGE, 2018, 26 : S5 - S6
  • [9] Critical thinking about adverse drug effects: Lessons from the psychology of risk and medical decision-making for clinical psychopharmacology
    Nierenberg, Andrew A.
    Smoller, Jordan W.
    Eidelman, Polina
    Wu, Yelena P.
    Tilley, Claire A.
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2008, 77 (04) : 201 - 208
  • [10] Safety of Computed Tomography in Patients With Cardiac Rhythm Management Devices Assessment of the US Food and Drug Administration Advisory in Clinical Practice
    Hussein, Ayman A.
    Abutaleb, Ameer
    Jeudy, Jean
    Phelan, Timothy
    Patel, Ronak
    Shkullaku, Melsjan
    Siddiqi, Faisal
    See, Vincent
    Saliaris, Anastasios
    Shorofsky, Stephen R.
    Dickfeld, Timm
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (17) : 1769 - 1775